



First-in-Class Antibody Therapeutics  
Anti-CTHRC1 for Multiple Solid Cancer

# PBP1710



PRESTIGE BIOPHARMA  
Innovative Discovery Center








# Mode of Action





## CTHRC1 promote progression of cancer via multiple ways

1. Directly promoting cancer cell growth and migration
2. Acting as a potent endothelial activator that promotes angiogenesis
3. Remodeling cancer ECM by activating cancer-associated fibroblasts (CAFs)



**PBP1710 blocks the pro-tumorigenic effects of CTHRC1**

## Efficacy



- ✓ PBP1710 inhibits tumorigenesis by affecting collagen deposition
- ✓ PBP1710 prevents metastasis by inhibiting the migration of cancer cells

# Pipeline Highlights

First-in-Class Antibody Therapeutics

## PBP1510 Anti-PAUF, Ulenistamab

FDA ORPHAN DRUG DESIGNATION FDA FAST TRACK DESIGNATION



### First-in-Class Antibody PBP1510 (Ulenistamab)

- Development stage : Phase 1/2a (EU, USA & Asia)
- Indication : Pancreatic cancer, Ovarian cancer
- Orphan Drug Designation by FDA, EMA, MFDS
- Fast Track Designation by FDA



### First-in-Class Antibody PBP1710 (Anti-CTHRC1)

- Development stage : Preclinical
- Indication : Solid tumors
- Patent registered in Korea in January 2023

Category	Pipeline	Indication	Development Stage
First-in-class	Ulenistamab (PBP1510)	Pancreatic cancer, Ovarian cancer	Clinical (Phase 1/2a)
	PBP1710	Solid tumor	Preclinical
	IDC111	Solid tumor	Basic Research
Bispecific Antibody	IDC001	Solid tumor	Basic Research
	IDC002	Solid tumor	Basic Research
	IDC003	Solid tumor	Basic Research
	IDC005	Solid tumor	Discovery
	IDC007	Critical immune disorders	Discovery
	IDC008	Solid tumor	Discovery
	IDC009	Solid tumor	Discovery
	IDC010	Immune disease	Discovery
Novel Concept Antibody	IDC331	Solid tumor	Discovery
	IDC332	Solid tumor	Discovery
	IDC333	Solid tumor	Discovery
	IDC334	Solid tumor	Discovery
Antibody Drug Conjugate	IDC441	Solid tumor	Basic Research



PRESTIGEBIOPHARMA



Youtube



Publication



**PRESTIGE BIOPHARMA**  
Innovative Discovery Center

### Corporate Headquarters

21 Biopolis Road, #04-24/28  
Nucleus South Building, Singapore 138567  
Tel: +65 6924 6535  
Email: info@prestigebio.com

### Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd.  
2776-8, Myeongji-dong, Gangseo-gu,  
Busan 618-814, South Korea  
Tel: +82 51 580 8000  
Email: idc@prestigebio.com